<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Institute for Medical Research</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2703A390-0A70-44A9-B34B-DC3B463A3B79"><gtr:id>2703A390-0A70-44A9-B34B-DC3B463A3B79</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Alexander</gtr:otherNames><gtr:surname>Nathan</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802822"><gtr:id>AA063171-7A49-4005-9444-45B238D59B37</gtr:id><gtr:title>The regulation of muscle atrophy by enzymes of the ubiquitin-proteasome system</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0802822</gtr:grantReference><gtr:abstractText>Muscle wasting is a disabling response to many common conditions, including infections, cancer and diabetes, driven by a rapid increase in protein breakdown. This wasting is particularly important in lung diseases, where weakness of the chest muscles may severely affect patients? longterm survival. In addition, several conditions may occur simultaneously, such as steroid treatment and immobility, which further increase the severity of muscle wasting. It is established that this rapid protein breakdown is mainly caused by activation of the ?ubiquitin system?. Ubiquitin is a small molecule that attaches to other proteins, signalling their destruction, and recent research has shown that several enzymes of the ubiquitin system are increased in muscle wasting. The ubiquitin system is regulated by deubiquitinating enzymes (DUBs), which remove ubiquitin from proteins. So far, the precise role of DUBs in muscle breakdown remains to be determined. In this project, I will study the function of DUBs in muscle wasting, and examine how different causes of protein breakdown combine to induce severe muscle loss. In particular, I will study how DUBs affect ubiquitin levels, and measure which genes are activated in muscle breakdown. These investigations will provide essential insights into how muscle wasting is stimulated and regulated.</gtr:abstractText><gtr:technicalSummary>Muscle atrophy is a debilitating response to many disease states, including sepsis, cachexia, starvation, acidosis and denervation, and it is firmly established that this muscle wasting is primarily due to enhanced proteolysis involving the ubiquitin-proteasome system. Accelerated protein breakdown is triggered by activation of Forkhead transcription factors (FoxOs) and expression of a distinct group of genes, which include components of the ubiquitin pathway (particularly 26S proteasome subunits and two atrophy-specific ubiquitin E3 ligases, MuRF1 and atrogin-1). While it is clear that induction of the ubiquitin-proteasome system is required for muscle atrophy, many of the molecular mechanisms remain to be determined: (i) physiological studies demonstrate that profound muscle atrophy can be induced by synergy between glucocorticoid treatment and muscle disuse/denervation, but the molecular mechanisms involved are not known, and (ii) although the level of ubiquitinated proteins dramatically increases in atrophying muscles, the role of deubiquitinating enzymes (DUBs) which prevent accumulation of ubiquitin conjugates, is not clear. Therefore, the aims of the project are to (1) determine the role of USP14, a proteasome-associated DUB, in muscle atrophy, (2) identify and elucidate the functions of novel DUBs involved in muscle atrophy using an siRNA depletion screen, and (3) determine the molecular basis of rapid atrophy caused by syngergy between glucocorticoids and disuse/denervation.
 (1) USP14 is upregulated during muscle atrophy but its functions have not been elucidated. I will first examine how USP14 protein levels change during muscle atrophy and determine whether USP14 is essential for accelerated protein breakdown following its siRNA-mediated depletion in cultured mytobes and in vivo. 26S proteasomes will then be isolated from atrophing muscles to elucidate how USP14 affects proteasome function. (2) To identify novel DUBs involved in muscle atrophy I propose to screen the effects of DUB siRNA depletion on degradation of MuRF1 substrates in cultured myotubes. Using a DUB siRNA library I will transduce cells expressing fluorescently tagged MuRF1 substrates and measure their degradation following muscle atrophy. Novel DUBs identified in this screen will be verified by measuring the effect of their siRNA depletion on overall proteolysis in cultured myotubes and in vivo. (3) Using Affymetrix chips I will examine the transcriptional profiles of atrophying muscles induced by glucocorticoids in combination with disuse/denervation. It is expected that these studies will help elucidate the function of DUBs in muscle atrophy as well as identify critical target genes involved in the synergistic atrophy response of glucocorticoids with disuse/denervation.</gtr:technicalSummary><gtr:fund><gtr:end>2013-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>618362</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Massachusetts (UMass)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Infectious Diseases and Immunology</gtr:department><gtr:description>Immunoproteasomes</gtr:description><gtr:id>C2106956-24AD-4866-B66B-0221BFFBC776</gtr:id><gtr:impact>Ongoing research into immunoproteasome function - results not yet published.</gtr:impact><gtr:outcomeId>B5pDUSu25bT-1</gtr:outcomeId><gtr:piContribution>Analysis of immunoproteasomes versus standard proteasomes in ability to degrade proteins.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Prions and Proteasomes</gtr:description><gtr:id>DE280B01-1F0F-4DD5-BC8E-03D4A45506DC</gtr:id><gtr:impact>Published results in EMBO -see publications</gtr:impact><gtr:outcomeId>T3zBvPshrht-1</gtr:outcomeId><gtr:partnerContribution>Collaborated on project to examine the effects of prions on proteasome function.</gtr:partnerContribution><gtr:piContribution>Experiments on proteasome gate opening</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine Service</gtr:department><gtr:description>Proteasome function in COPD</gtr:description><gtr:id>50748266-2F7C-4DD0-BCCE-BC25FFC45760</gtr:id><gtr:impact>Study examining muscle protein breakdown and proteasome function.</gtr:impact><gtr:outcomeId>d6uTsN8Z8mK-1</gtr:outcomeId><gtr:piContribution>Input into study design and co-supervision of post-doctoral fellow.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Futures of Science Scholarship</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Keystone Symposia on Molecular and Cellular Biology</gtr:fundingOrg><gtr:id>71ABE6D1-429A-4906-B835-619FB27EA1FE</gtr:id><gtr:outcomeId>NGRbHbsHxTK</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E0B9F9CD-0C6B-40DF-BCF5-85AEA06E77FD</gtr:id><gtr:title>Muscle wasting in disease: molecular mechanisms and promising therapies.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/157da1042010ee68dc490cff812ee7e9"><gtr:id>157da1042010ee68dc490cff812ee7e9</gtr:id><gtr:otherNames>Cohen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>5675de3875fb3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F85277E4-F664-4595-B90C-1C7D83B2BEFB</gtr:id><gtr:title>The ATP costs and time required to degrade ubiquitinated proteins by the 26 S proteasome.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96bdbda368d8a359eacabe927dddaee1"><gtr:id>96bdbda368d8a359eacabe927dddaee1</gtr:id><gtr:otherNames>Peth A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_15506_26_23965995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5FB0BC3-07A4-47B6-B788-D39D4BB43868</gtr:id><gtr:title>Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/193c3f67cc0e02baa5ad5779f7aa9c10"><gtr:id>193c3f67cc0e02baa5ad5779f7aa9c10</gtr:id><gtr:otherNames>Nathan JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>pm_15506_26_23452861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>149F9630-B188-4DF4-AFEC-2677F9E5AABC</gtr:id><gtr:title>TMEM129 is a Derlin-1 associated ERAD E3 ligase essential for virus-induced degradation of MHC-I.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f960576a028c54619b3dd526a2eb7e5"><gtr:id>3f960576a028c54619b3dd526a2eb7e5</gtr:id><gtr:otherNames>van den Boomen DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>585d525b734d69.08036118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1629123B-1BF7-4B29-8726-D27298CE7523</gtr:id><gtr:title>Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes?</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/193c3f67cc0e02baa5ad5779f7aa9c10"><gtr:id>193c3f67cc0e02baa5ad5779f7aa9c10</gtr:id><gtr:otherNames>Nathan JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>pm_15506_26_23314748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F02C3A74-CDFC-4D6A-BEC1-98317CF69C8D</gtr:id><gtr:title>Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1db431be05506d4cf0ba9a69ddecabf4"><gtr:id>1db431be05506d4cf0ba9a69ddecabf4</gtr:id><gtr:otherNames>Deriziotis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>qpkTxG5eXLi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1ECCA62-BB7B-437B-B053-667BD7298C95</gtr:id><gtr:title>The Proteasome Distinguishes between Heterotypic and Homotypic Lysine-11-Linked Polyubiquitin Chains.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43e96202ecca6a8338af2bb4b2eafa6d"><gtr:id>43e96202ecca6a8338af2bb4b2eafa6d</gtr:id><gtr:otherNames>Grice GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>585d537a0bc281.58224356</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11A26841-3D3A-4A8B-95E7-369067453868</gtr:id><gtr:title>Cleavage by signal peptide peptidase is required for the degradation of selected tail-anchored proteins.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeed9b26eaeb5e8deb421da7d5b49425"><gtr:id>aeed9b26eaeb5e8deb421da7d5b49425</gtr:id><gtr:otherNames>Boname JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>545a5ff7da6163.11797571</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802822</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>